Parathyroid tumors

被引：14

作者：

Tobias Carling

Robert Udelsman

机构：

[1] Department of Surgery, Yale University School of Medicine, 330 Cedar Street, FMB 102, Box 208062, New Haven, 06510, CT

来源：

Current Treatment Options in Oncology | 2003年 / 4卷 / 4期

关键词：

Hypercalcemia; Main Drug Interaction; Parathyroid Adenoma; Parathyroid Gland; Primary Hyperparathyroidism;

D O I：

10.1007/s11864-003-0007-x

中图分类号：

学科分类号：

摘要：

Parathyroid tumors causing primary hyperparathyroidism are common and often remain undiagnosed, despite that the diagnostic work-up is uncomplicated in most patients. The patients often do not receive the appropriate curative treatment, which is surgical. Recent studies show that surgery is beneficial in patients with mild asymptomatic disease, especially in the reversal of bone disease, neuropsychologic symptoms, and dyslipoproteinemia. All patients with the disease deserve a referral to an endocrine surgeon for discussions regarding surgical intervention. Minimally invasive techniques performed in the ambulatory setting have evolved rapidly and show an extraordinary high success rate, low-morbidity rate, and are likely to become the standard treatment for most patients with primary hyperparathyroidism. © 2003, Current Science Inc.

引用

页码：319 / 328

页数：9

共 29 条

[1]

Carling T., Molecular pathology of parathyroid tumors, Trends Endocrinol Metab, 12, pp. 53-58, (2001)

[2]

Lundgren E., Rastad J., Akerstrom G., Ljunghall S., Population-based health screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women, Surgery, 121, pp. 287-294, (1997)

[3]

Melton L.J., The epidemiology of primary hyperparathyroidism in North America, J Bone Miner Res, 17, pp. N12-N17, (2002)

[4]

Marx S.J., Simonds W.F., Agarwal S.K., Et al., Hyperparathyroidism in hereditary syndromes: special expressions and special managements, J Bone Miner Res, 17, pp. N37-N43, (2002)

[5]

Chattopadhyay N., Mithal A., Brown E.M., The calciumsensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism, Endocrine Rev, 17, pp. 289-307, (1996)

[6]

Carling T., Rastad J., Szabo E., Et al., Reduced vitamin D receptor mRNA levels in parathyroid glands of primary and secondary hyperparathyroidism, J Clin Endocrinol, 85, pp. 2000-2003, (2000)

[7]

Farnebo F., Enberg U., Grimelius L., Et al., Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism, J Clin Endocrinol Metab, 82, pp. 3481-3486, (1997)

[8]

Carling T., Kindmark A., Hellman P., Et al., Vitamin D receptor genotypes in primary hyperparathyroidism, Nat Med, 1, pp. 1309-1311, (1995)

[9]

Carpten J.D., Robbins C.M., Villablanca A., Et al., HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome, Nat Genet, 32, pp. 676-680, (2002)

[10]

Bilezikian J., Potts J.J., Fuleihan G.H., Et al., Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century, J Clin Endocrinol Metab, 87, pp. 5353-5361, (2002)

← 1 2 3 →